ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
38.73
-0.72%
US Tech 100
18,777.20
-0.70%
S&P 500
5,531.29
-1.48%
US Dollar vs CAD
1.44918
0.42%
Bitcoin
81,112.11
3.36%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Geron Corp (GERN) Share Price

Geron Corp

Geron Corp (GERN)

NASDAQ
1.595
-0.015
( -0.93% )
Updated: 12:11:13
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
1.595
Bid
1.59
Ask
1.60
Volume
6,361,474
1.57 Day's Range 1.63
1.4601 52 Week Range 5.34
Market Cap
1.016B
Previous Close
1.61
Open
1.59
Last Trade
100
@
1.595
Last Trade Time
12:11:17
Financial Volume
US$ 10,134,542
VWAP
1.5931
Average Volume (3m)
15,633,936
Shares Outstanding
636,904,470
Dividend Yield
-
PE Ratio
-5.50
Earnings Per Share (EPS)
-0.29
Revenue
237k
Net Profit
-184.13M

About Geron Corp

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a ... Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses global rights to this drug. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.geron.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Geron Corp is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker GERN. The last closing price for Geron was US$1.61. Over the last year, Geron shares have traded in a share price range of US$ 1.4601 to US$ 5.34.

Geron currently has 636,904,470 shares outstanding. The market capitalization of Geron is US$1.03 billion. Geron has a price to earnings ratio (PE ratio) of -5.50.

Ask ADVFN Intelligence (AI)

GERN Latest News

More News

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
March 03 2025
GERN (-0.93%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
March 03 2025
GERN (-0.93%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
March 03 2025
GERN (-0.93%)

Form 8-K - Current report
Edgar (US Regulatory)
January 13 2025
GERN (-0.93%)

Form S-8 - Securities to be offered to employees in employee benefit plans
Edgar (US Regulatory)
January 10 2025
GERN (-0.93%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.105-6.176470588241.71.81.57169869181.67938076CS
4-1.195-42.83154121862.792.8351.4601205896032.00519104CS
12-2.215-58.13648293963.8141.4601156339362.65007248CS
26-2.735-63.16397228644.334.8251.4601114620223.26480676CS
52-0.665-29.42477876112.265.341.4601118412923.61944757CS
1560.495451.15.341.0174952753.03801533CS
2600.58557.92079207921.015.340.7558224462.7173809CS

GERN - Frequently Asked Questions (FAQ)

What is the current Geron share price?
The current share price of Geron is US$ 1.595
How many Geron shares are in issue?
Geron has 636,904,470 shares in issue
What is the market cap of Geron?
The market capitalisation of Geron is USD 1.03B
What is the 1 year trading range for Geron share price?
Geron has traded in the range of US$ 1.4601 to US$ 5.34 during the past year
What is the PE ratio of Geron?
The price to earnings ratio of Geron is -5.5
What is the cash to sales ratio of Geron?
The cash to sales ratio of Geron is 3.98k
What is the reporting currency for Geron?
Geron reports financial results in USD
What is the latest annual turnover for Geron?
The latest annual turnover of Geron is USD 237k
What is the latest annual profit for Geron?
The latest annual profit of Geron is USD -184.13M
What is the registered address of Geron?
The registered address for Geron is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Geron website address?
The website address for Geron is www.geron.com
Which industry sector does Geron operate in?
Geron operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
RAYRaytech Holding Ltd
US$ 2.015
(131.61%)
66.37M
SYRSSyros Pharmaceuticals Inc
US$ 0.176
(92.14%)
624.58M
TSVT2seventy bio Inc
US$ 4.95
(76.79%)
28.8M
HSAIHesai Group
US$ 21.94
(37.04%)
20.96M
METCRamaco Resources Inc
US$ 11.15
(32.74%)
1.89M
WCTWellchange Holdings Company Limited
US$ 0.6099
(-75.70%)
23.45M
ARVNArvinas Inc
US$ 8.05
(-54.16%)
11.45M
LZMHLZ Technology Holdings Ltd
US$ 9.32
(-40.49%)
432.6k
KBSXFST Corporation
US$ 3.48
(-34.34%)
32.42k
ARBBARB IOT Group Ltd
US$ 0.6826
(-31.74%)
1.91M
SYRSSyros Pharmaceuticals Inc
US$ 0.1761
(92.25%)
617.73M
BHATBlue Hat Interactive Entertainment Technology
US$ 0.0426
(27.16%)
369.37M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 7.62
(3.25%)
220.3M
NVDANVIDIA Corporation
US$ 108.02
(0.97%)
204.41M
CUTRCutera Inc
US$ 0.123
(-4.28%)
201.66M

GERN Discussion

View Posts
KIPK KIPK 6 days ago
LOLC-2020...

SMH
👍️0
learningcurve2020 learningcurve2020 1 week ago
Oh wow, nice! I hadn’t noticed. Always encouraging. Hopefully more to come.
👍️0
luckygm luckygm 1 week ago
The insiders were bullish buying shares on the open market last Thursday.
👍️0
KIPK KIPK 2 weeks ago
Its the "Too Little Tooo Late" story for GERN..
LOLC??? SMH
KARMA
👍️0
learningcurve2020 learningcurve2020 2 weeks ago
Shouldn’t be down here but it is. Analyst are all over the place. Institutional holdings look good so far unless they’re dumping. We need a more dynamic management, IMO.

“B. Riley downgrades to Neutral from Buy, Cuts target to $2 from $3.50”
👙 1
big bambino big bambino 2 weeks ago
looking for 2.25 by next week
👍️0
seward seward 2 weeks ago
Sold the15K at 1.75
👍️0
learningcurve2020 learningcurve2020 2 weeks ago
That’s all I need too. You know their governance over on the other board is atrocious, right? Rarely leads to anything good. At least Geron’s management bench runs deep. I wish they’d be more active with open market purchases but if the company is really in takeover mode that wouldn’t be possible, of course. Three presentations coming in the next weeks. We’ll see.
👍️0
attilathehunt attilathehunt 2 weeks ago
Here we agree. On the other board not so much.

By the way, I only have one account on ihub.
👍️0
learningcurve2020 learningcurve2020 2 weeks ago
It would be one explanation for the action today and faux stock downgrades.

“Wedbush Lowers Geron’s Price Target to $7 from $8, Outperform Raiting Maintained”
👍️0
attilathehunt attilathehunt 2 weeks ago
The takedown before the buyout!!

The same happen with HGSI
👍 1 💯 1
KIPK KIPK 2 weeks ago
LOLC2020 - You pumped it, Its failing & you now saying "THE COMPANY IS SOLID", BUT the "ANALYSTS SEEM INTENT ON SETTING THE STOCK FOR FAILURE??

Who pays you for such misjudged PUMP Efforts here & FUD Efforts there???
👍️0
learningcurve2020 learningcurve2020 2 weeks ago
This would be a very good time for some open market purchases by management.
👍️0
learningcurve2020 learningcurve2020 2 weeks ago
The company seems solid but the analyst seem intent on setting up the stock for failure.
👍️0
learningcurve2020 learningcurve2020 2 weeks ago
And you think someone would believe that why?
👍️0
big bambino big bambino 2 weeks ago
Great purchase. picked up another 5k @ 1.92
👍️0
learningcurve2020 learningcurve2020 2 weeks ago
All seems good but the stock is always a death trap.

>>Selling, general and administrative expenses for the three and twelve months ended December 31, 2024, were $43.4 million, and $145.7 million, respectively, and $21.4 million and $69.1 million for the same periods in 2023. The increase in general and administrative expenses in 2024 as compared to 2023 primarily reflects higher personnel-related expenses related to increased headcount to support commercial launch of RYTELO in the U.S. and stock-based compensation expense recognized upon FDA approval of RYTELO due to the vesting of performance-based stock options.
👍️0
seward seward 2 weeks ago
picked up another 10000 at 1.60

👍️0
learningcurve2020 learningcurve2020 2 weeks ago
Grrron stock is just a disgrace…A perpetual retail trap.
💯 1
big bambino big bambino 2 weeks ago
picked up another 4500@ $2.40
👍️0
big bambino big bambino 2 weeks ago
pushing this thing down low with no news and no volume, amazing. Will wait till Wednesday before making decision.
👍️0
KIPK KIPK 3 weeks ago
But in your Case, LC2020, a response from GROK not needed as ihub has all of YOU!!!
🪠 1
KIPK KIPK 3 weeks ago
You have been made - Historical/Present Records Been Collected!!

KARMA!!
🪠 1
Stumblebum Stumblebum 3 weeks ago
Earnings next week….looking for revs in the $40-$50 mil range…..up nicely from last quarter…hopefully some sort of update on European drug approval….that should happen mid year….only way to go is up from here
👍️ 1
learningcurve2020 learningcurve2020 3 weeks ago
What are you babbling about now?
👍️0
KIPK KIPK 3 weeks ago
LC-2020,

You know Your Effort to Earn are Well Documented, RIGHT??

KARMA
👍️0
learningcurve2020 learningcurve2020 3 weeks ago
A coming next week.
👍️0
learningcurve2020 learningcurve2020 3 weeks ago
WTF! Is Geron stock just a forever retail trap or are we going to see a real run?

“B. Riley Adjusts target to $3.50 From $5.50, Maintains Buy Rating”
👍️0
KIPK KIPK 3 weeks ago
LOL -LC2020: And as per your folowing post..

>>> That should give them about another month to dump shares before we learn anything>>>

There has never been "WE". You paid to work against the "WE", you pretend to be part of...
KARMA!!!!
🪠 1
learningcurve2020 learningcurve2020 4 weeks ago
Grrrrron. So disappointing. Hopefully just a shake out before the coming q report.
👍️0
learningcurve2020 learningcurve2020 4 weeks ago
What do you mean, I’ve been somewhat supportive of Geron?
👍️0
learningcurve2020 learningcurve2020 4 weeks ago
You and the other disciples always get it wrong.

KEEP SINGING DEMOCRATS -- AND DOGE WILL KEEP CUTTING.pic.twitter.com/5lYnlI2Qlq— Citizen Free Press (@CitizenFreePres) February 12, 2025
👍️ 1
learningcurve2020 learningcurve2020 1 month ago
Hopefully market acceptance increasing. Buyout is always on the table now that they said they likely won’t do a cash raise. I’m hoping for some long-shot unexpected benefit suddenly seen in some other indication.
👍️0
Stumblebum Stumblebum 1 month ago
Better than expected revenues? Date when they expect European approval?…..I’m buying call options !!!!!!…..not shares
👍️0
big bambino big bambino 1 month ago
Someone knows something? High volume the last week, with a sizeable uptick.
👍️0
learningcurve2020 learningcurve2020 1 month ago
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its fourth quarter and full-year 2024 financial results and business highlights before the market opens on Wednesday, February 26, 2025 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as business highlights at 8:00 a.m. Eastern Time the same day.
👍️0
KIPK KIPK 2 months ago
You are a Karmic Poison to You!!
👍️0
learningcurve2020 learningcurve2020 2 months ago
https://s201.q4cdn.com/710325604/files/doc_presentations/2025/Jan/13/JPM-2025-Corporate-Slides_final-2.pdf
👍️0
learningcurve2020 learningcurve2020 2 months ago
Who knows?? IBB is going sideways, New POTUS, nervous market. Perhaps a buyout is coming?? Perhaps something we’re not being told?? You never know in the biotech space. But all I can say is Geron has never looked better in the decades I’ve been around.
👍️0
attilathehunt attilathehunt 2 months ago
why the stock is doing so poorly

The MMs are on the hook for too many options in the money above $3....Wait for move next week.
👍️0
Spike5 Spike5 2 months ago
Ok fair enough but tell me why the stock is doing so poorly
👍️0
learningcurve2020 learningcurve2020 2 months ago
Umm…what I put in quotes maybe? ~$45M in net revs for 2024 with hopefully full Rytelo market acceptance in 2025 and other indications to come. Quickly growing up. I like it.
👍️0
Spike5 Spike5 2 months ago
I’m curious as to what looks good about this to you . Please enlighten me
👍️0
learningcurve2020 learningcurve2020 2 months ago
LOL. Looks good to me. “Positioned for Profitability Without Additional Financing”.
👍️0
learningcurve2020 learningcurve2020 2 months ago
Ugly. 8k out. What am I missing?
👍️0
Spike5 Spike5 2 months ago
It’s getting exactly what I said it would get . I hope some people listened to me and sold and did not listen to the morons on this board . You know who they are
👍️0
Monksdream Monksdream 2 months ago
GERN. 10 day hourly
👍️0
big bambino big bambino 2 months ago
Heavy accumulation 😆
👍️0
KIPK KIPK 2 months ago
LC2020. Posting Paid trash 24/7 is his very proud way of living...

SMH,,,, KARMIC Trap....
👍️0
big bambino big bambino 3 months ago
I agree, that is why I keep adding. product approved with great results. Just waiting for the true breakout 😃
👍️ 1

Your Recent History

NASDAQ
GERN
Geron
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads